Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 33399940)

  • 1. Enhancing the activity of platinum-based drugs by improved inhibitors of ERCC1-XPF-mediated DNA repair.
    Ciniero G; Elmenoufy AH; Gentile F; Weinfeld M; Deriu MA; West FG; Tuszynski JA; Dumontet C; Cros-Perrial E; Jordheim LP
    Cancer Chemother Pharmacol; 2021 Feb; 87(2):259-267. PubMed ID: 33399940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of the ERCC1-XPF structure-specific endonuclease to overcome cancer chemoresistance.
    McNeil EM; Astell KR; Ritchie AM; Shave S; Houston DR; Bakrania P; Jones HM; Khurana P; Wallace C; Chapman T; Wear MA; Walkinshaw MD; Saxty B; Melton DW
    DNA Repair (Amst); 2015 Jul; 31():19-28. PubMed ID: 25956741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small molecule inhibitors of ERCC1-XPF protein-protein interaction synergize alkylating agents in cancer cells.
    Jordheim LP; Barakat KH; Heinrich-Balard L; Matera EL; Cros-Perrial E; Bouledrak K; El Sabeh R; Perez-Pineiro R; Wishart DS; Cohen R; Tuszynski J; Dumontet C
    Mol Pharmacol; 2013 Jul; 84(1):12-24. PubMed ID: 23580445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of small molecule inhibitors of ERCC1-XPF that inhibit DNA repair and potentiate cisplatin efficacy in cancer cells.
    Arora S; Heyza J; Zhang H; Kalman-Maltese V; Tillison K; Floyd AM; Chalfin EM; Bepler G; Patrick SM
    Oncotarget; 2016 Nov; 7(46):75104-75117. PubMed ID: 27650543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple roles of the ERCC1-XPF endonuclease in DNA repair and resistance to anticancer drugs.
    Kirschner K; Melton DW
    Anticancer Res; 2010 Sep; 30(9):3223-32. PubMed ID: 20944091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the DNA Repair Endonuclease ERCC1-XPF with Green Tea Polyphenol Epigallocatechin-3-Gallate (EGCG) and Its Prodrug to Enhance Cisplatin Efficacy in Human Cancer Cells.
    Heyza JR; Arora S; Zhang H; Conner KL; Lei W; Floyd AM; Deshmukh RR; Sarver J; Trabbic CJ; Erhardt P; Chan TH; Dou QP; Patrick SM
    Nutrients; 2018 Nov; 10(11):. PubMed ID: 30400270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells.
    Arora S; Kothandapani A; Tillison K; Kalman-Maltese V; Patrick SM
    DNA Repair (Amst); 2010 Jul; 9(7):745-53. PubMed ID: 20418188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and in vitro cell-free/cell-based biological evaluations of novel ERCC1-XPF inhibitors targeting DNA repair pathway.
    Elmenoufy AH; Gentile F; Jay D; Karimi-Busheri F; Yang X; Soueidan OM; Mani RS; Ciniero G; Tuszynski JA; Weinfeld M; West FG
    Eur J Med Chem; 2020 Oct; 204():112658. PubMed ID: 32738410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanoparticle-Mediated Gene Silencing for Sensitization of Lung Cancer to Cisplatin Therapy.
    Feldmann DP; Heyza J; Zimmermann CM; Patrick SM; Merkel OM
    Molecules; 2020 Apr; 25(8):. PubMed ID: 32344513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computer-aided drug design of small molecule inhibitors of the ERCC1-XPF protein-protein interaction.
    Gentile F; Elmenoufy AH; Ciniero G; Jay D; Karimi-Busheri F; Barakat KH; Weinfeld M; West FG; Tuszynski JA
    Chem Biol Drug Des; 2020 Apr; 95(4):460-471. PubMed ID: 31891209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computational Characterization of Small Molecules Binding to the Human XPF Active Site and Virtual Screening to Identify Potential New DNA Repair Inhibitors Targeting the ERCC1-XPF Endonuclease.
    Gentile F; Barakat KH; Tuszynski JA
    Int J Mol Sci; 2018 Apr; 19(5):. PubMed ID: 29710850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular docking and molecular dynamics study on the effect of ERCC1 deleterious polymorphisms in ERCC1-XPF heterodimer.
    Priya Doss CG; Nagasundaram N
    Appl Biochem Biotechnol; 2014 Feb; 172(3):1265-81. PubMed ID: 24158589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA repair endonuclease ERCC1-XPF as a novel therapeutic target to overcome chemoresistance in cancer therapy.
    McNeil EM; Melton DW
    Nucleic Acids Res; 2012 Nov; 40(20):9990-10004. PubMed ID: 22941649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting DNA Repair in Tumor Cells via Inhibition of ERCC1-XPF.
    Elmenoufy AH; Gentile F; Jay D; Karimi-Busheri F; Yang X; Soueidan OM; Weilbeer C; Mani RS; Barakat KH; Tuszynski JA; Weinfeld M; West FG
    J Med Chem; 2019 Sep; 62(17):7684-7696. PubMed ID: 31369707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetics of platinum-based chemotherapy in non-small cell lung cancer: predictive validity of polymorphisms of ERCC1.
    Hamilton G; Rath B
    Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):17-24. PubMed ID: 29226731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of domains for protein-protein interaction of nucleotide excision repair proteins modifies cancer cell sensitivity to platinum derivatives and genomic stability.
    Jordheim LP; Cros-Perrial E; Matera EL; Bouledrak K; Dumontet C
    Clin Exp Pharmacol Physiol; 2014 Oct; 41(10):817-24. PubMed ID: 25115435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-arm, open label prospective trial to assess prediction of the role of ERCC1/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapy.
    Ganzinelli M; Linardou H; Alvisi MF; Caiola E; Lo Russo G; Cecere FL; Bettini AC; Psyrri A; Milella M; Rulli E; Fabbri A; De Maglie M; Romanelli P; Murray S; Broggini M; Marabese M; Garassino MC
    ESMO Open; 2021 Feb; 6(1):100034. PubMed ID: 33422766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Applications of genomics in NSCLC.
    Rosell R; Cobo M; Isla D; Sanchez JM; Taron M; Altavilla G; Santarpia M; Moran T; Catot S; Etxaniz O
    Lung Cancer; 2005 Dec; 50 Suppl 2():S33-40. PubMed ID: 16557672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New design of nucleotide excision repair (NER) inhibitors for combination cancer therapy.
    Gentile F; Tuszynski JA; Barakat KH
    J Mol Graph Model; 2016 Apr; 65():71-82. PubMed ID: 26939044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression.
    Usanova S; Piée-Staffa A; Sied U; Thomale J; Schneider A; Kaina B; Köberle B
    Mol Cancer; 2010 Sep; 9():248. PubMed ID: 20846399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.